Methods of treating and preventing influenza infections

1. A method of treating, preventing, or inhibiting symptoms of an influenza virus infection comprising:

providing an immunogenic preparation that contains at least two peptides, wherein at least one of the two peptides comprises an amino acid sequence that is at least 95% identical to any one of SEQ ID NOs: 6, 14-17, 47, and 54-55; and at least one of the two peptides comprises a T-cell stimulating epitope; and

administering the immunogenic preparation to a patient to generate an immunological response to the infection.

2. The method of claim 1 , wherein the influenza virus comprises one or more of H1N1, H1N7, H2N2, H3N1, H3N2, H3N8, H5N1, H5N2, H5N3, H5N8, H5N9, H7N1, H7N2, H7N3, H7N4, H7N7 or H9N2.

3. The method of claim 1 , wherein at least one peptide comprises the sequence of SEQ ID NO 6.

4. The method of claim 1 , wherein at least one peptide comprises the sequence of SEQ ID NO 14.

5. The method of claim 1 , wherein at least one peptide comprises the sequence of SEQ ID NO 15.

6. The method of claim 1 , wherein at least one peptide comprises the sequence of SEQ ID NO 16.

7. The method of claim 1 , wherein at least one peptide comprises the sequence of SEQ ID NO 17.

8. The method of claim 1 , wherein at least one peptide comprises the sequence of SEQ ID NO 54.

9. The method of claim 1 , wherein at least one peptide comprises the sequence of SEQ ID NO 55.

10. The method of claim 1 , wherein each of the at least two peptides comprises an amino acid sequence that is at least 95% identical to any one of SEQ ID NOs: 6, 14-17, 47, and 54-55.

11. The method of claim 1 , wherein the T-cell stimulating epitope comprises a fragment, derivative, or variant of CRM, diphtheria toxoid, tetanus toxoid, lipoprotein, or combinations thereof.

12. The method of claim 1 , wherein the at least two peptides and the T-cell stimulating epitope are conjugated.

13. The method of claim 1 , wherein the immune response comprises a cellular or antibody-mediated immune response against the infection.

14. The method of claim 13 , wherein the cellular or antibody-mediated immune response comprises one or more of production of antibodies, B cells, T Helper cell, or cytotoxic T cells directed against the infection.

15. The method of claim 1 , wherein the immunogenic preparation comprises an adjuvant.

16. The method of claim 1 , wherein the immunogenic preparation does not include an adjuvant.

17. The method of claim 1 , wherein the immunogenic preparation is formulated for local or system administration.

18. The method of claim 1 , wherein the immunogenic preparation is formulated as microcapsules, microparticles, microspheres, nanocapsules, nanoparticles, nanospheres, or combinations thereof.

19. The method of claim 1 , wherein administering comprises a single dose of the immunogenic preparation.

20. The method of claim 1 , wherein administering comprises multiple doses of the immunogenic preparation.

21. The method of claim 1 , wherein administration is intradermal, intramuscular, intranasal, intravenous, oral, parenteral, subcutaneous, transcutaneous, or transdermal.

22. The method of claim 1 , wherein administration is a prophylactically or therapeutically effective amount.

23. A method of treating, preventing, or inhibiting symptoms of an influenza virus infection comprising:

providing an immunogenic preparation that contains at least two peptides, wherein at least one of the two peptides comprises an amino acid sequence that is at least 95% identical to any one of SEQ ID NOs: 6, 14-17, 47, and 54-55; and at least one of the two peptides comprises a T-cell stimulating epitope;

administering the immunogenic preparation to a mammal to generate an immunological response containing antibodies responsive to the immunogenic preparation; and

collecting antibodies generated.

24. The method of claim 23 , further comprising administering the antibodies collected to a patient suspected of having or actually having an influenza virus infection.

25. A method of treating, preventing or inhibiting symptoms of an influenza virus infection, comprising:

providing an immunogenic preparation that contains a composite antigen, wherein said composite antigen comprises a sequence derived from two different antigenic epitopes,

wherein the two different antigenic epitopes comprise similar sequences at the N- and C-terminal portions and a different amino acid sequences in the middle portion, and wherein said two different epitopes are derived from the one or more pathogens,

wherein said composite antigen comprises the formula A1BCA2, wherein:

1) A1 is the consensus sequence between the two epitopes that are the common amino acids at the N-terminus of each epitope, and wherein A1 is less than 30 amino acids;

2) B represents the one or two middle amino acid residue(s) from the first epitope that differ from the second epitope;

3) C represents the one or two middle amino acid residue(s) from the second epitope that differ from the first epitope;

4) A2 is the consensus sequence between the two epitopes that are the common amino acids at the C-terminus of each epitope, and wherein A2 is less than 30 amino acids;

administering the immunogenic preparation to a patient to generate an immunological response to the infection.

26. The method of claim 25 , wherein said antigen is linked to one or more additional epitopes, one or more additional composite epitopes, or a combination thereof.

27. The method of claim 25 , wherein the antigenic epitopes are derived from M1, M2, HA, NA, PB1, or PB2 proteins of Influenza virus, or a combination thereof.

28. The method of claim 25 , wherein the two different antigenic epitopes comprise SEQ ID NOs 4 and 5, or SEQ ID NOs 80 and 81, or SEQ ID NOs 83 and 84.

29. The method of claim 25 , wherein the composite antigenic sequence comprises SEQ ID NOs: 6, 21, 22, 54, 55, 58, 59, 82, 85, or 86.

30. The method of claim 25 , wherein the different epitopes of the immunogenic composition are derived from different serotypes of influenza virus.